The USFDA has approved ritlecitinib for treating severe alopecia areata, an autoimmune disease, in adults and adolescents who are 12 years of age or older. Alopecia areata causes hair fallout due to the immune system’s attack on the hair follicles. It involves the scalp region and is characterized by patchy hair loss. Mode of action of ritlecitinib Ritlecitinib is a covalent kinase inhibitor with high selectivity for Janus kinase 3 (JAK3).
It works by blocking the signaling of cytokines and cytolytic activity of T cells, which play a crucial role in the pathogenesis of alopecia areata. Dosage Ritlecitinib capsules can be taken orally once daily. Clinical trial (ALLEGRO) The FDA approval for ritlecitinib was based on the findings of the ALLEGRO Phase 2b/3 trial, which enrolled 718 patients with 50% or more scalp hair loss. The results indicated that 23% of patients treated with 50 mg…
